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Abstract: Abuse of antitussive preparations is a continuing problem in the United States and 
throughout the world. Illicit, exploratory, or recreational use of dextromethorphan and codeine/
promethazine cough syrups is widely described. This review describes the pharmacology, clinical 
effects, and management of toxicity from commonly abused antitussive formulations.
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Introduction
An article published in The Lancet in May 2007 highlighted a major growing health 
problem in the United States: abuse of pharmaceutical drugs. Experts ascribe the rise 
in the abuse of prescription drugs to the increased availability of these drugs, grow-
ing social acceptance of sedatives, painkillers, and anti-anxiety medications; and the 
perception, especially among young people, that pharmaceutical drugs are safe.1
Abuse of over the counter (OTC) antitussive preparations is a continuing problem in 
the United States and throughout the world. In 2008, the Substance Abuse and Mental 
Health Services Administration released the Annual National Survey on Drug Use and 
Health report, which revealed that in 2006 around 3.1 million people in the United States 
aged 12–25 stated that they had used OTC cough and cold medicine to “get high.”2
Since the early 1990s, there have been numerous reports of codeine cough syrup 
abuse from India, Japan, People’s Republic of China, and the United States.3–7 In 
addition, dextromethorphan misuse and abuse among children and adolescents has 
been well documented for decades.8,9 According to the 2011 report by the American 
Association of Poison Control Centers (AAPCC) National Poison Data System, which 
monitors the average annual prevalence of dextromethorphan abuse, there seems to 
be a plateau that has occurred since 2006.10 The explanation is likely multifactorial 
and based upon a combination of legislative, educational, and economic initiatives.11 
Perhaps there has been a shift to abuse of other more popular, readily available, and 
easily attainable cough and cold preparations, such as those containing codeine.
Since the late 1990s, abuse of codeine promethazine hydrochloride cough syrup 
(CPHCS) has become a growing public health problem, particularly in the southern 
United States.12 Known by the street names “lean”, “drank”, “barre”, “purple stuff ”, 
“syrup”, and “sizzurp”, abuse of CPHCS has become more popular since the late 
Houston-native rap artist/producer DJ Screw created a genre of music, aptly called 
“screw music,” inspired by intoxication on codeine and promethazine.13 Recently, 
many star athletes and celebrities have been profiled by the national media as a result 
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of their association with, and abuse of, CPHCS. Former 
National Football League quarterback Jamarcus Russell was 
arrested in 2010 for possession of large amounts of codeine 
without a prescription.13 In March 2013, famous hip-hop rap-
per Lil Wayne spent several days in an intensive care unit at 
a Los Angeles hospital after suffering seizures as a result of 
 “sizzurp” overdose and intoxication.14 Interestingly, DJ Screw 
died in November 2000 of an apparent multi-substance 
overdose including codeine which came from prescription-
strength cough syrup.15
Despite media attention and the well documented dan-
gers of cough syrup abuse for years, including a recent 2011 
study by Hou et al, which associated chronic codeine cough 
syrup abuse to alterations in the dopaminergic system and 
serious brain damage, abuse of these preparations remains 
rampant.16 The 29th Annual Report of the AAPCC National 
Poison Data System published in December 2012, documents 
74,995 exposures to cold and cough preparations. This 
accounts for 2.73% of all exposures called into United States 
poison centers and ranks “cold and cough preparations” 
number eleven on the list of top 25 substance categories most 
frequently involved in human exposures. Over 9,400 (12.5%) 
of the exposures to cough and cold preparations were the 
result of intentional abuse or misuse.17
Pharmacology and abuse  
potential of antitussives
Antitussives elicit their clinical affect by directly inhibit-
ing the medullary cough center of the brain.18 Codeine and 
dextromethorphan are two opioid agents with cough sup-
pressant activity. Various models suggest that cough suppres-
sion occurs via agonism of the µ
2
 or κ opioid receptors, or 
antagonism of the δ opioid receptor. The σ or N-methyl-d-
aspartate (NMDA) receptors are likely also involved.19–21
Dextromethorphan
Dextromethorphan is a dissociative agent, similar to ketamine 
and phencyclidine. Dextromethorphan contains an alkylated 
amine adjacent to a cyclohexane ring; a structural moiety 
common to the dissociative agents.8 Dextromethorphan has 
equal antitussive effects as codeine but does not possess 
analgesic or addictive properties.22
Dextromethorphan reaches maximum serum concentra-
tions in 2.5 hours after ingestion.23 The major metabolite 
of dextromethorphan, dextrorphan, achieves peak plasma 
concentrations at 1.6 to 1.7 hours following ingestion.24 
The volume of distribution of dextromethorphan in humans 
is thought to be 5.0–6.7 L/kg.25 Dextromethorphan and its 
metabolites undergo renal elimination, with less than 0.1% of 
the drug being eliminated in the feces.25 The half-life of the 
parent compound is approximately 2–4 hours in individuals 
with normal metabolism.8
Dextromethorphan is metabolized by cytochrome 
CYP2D6. In humans, CYP2D6 is a genetically polymorphic 
enzyme responsible for metabolizing numerous substances.26 
Rapid metabolizers (those individuals with extensive CYP2D6 
activity and, hence, increased rates of dextrometh orphan 
metabolism) constitute about 85% of the United States 
population and are more likely to abuse dextromethorphan 
because they get a quicker, more intense high. Dextrometho-
rphan undergoes 3-demethylation to dextrorphan and, to a 
lesser extent, N-demethylation to 3-methoxymorphinan.24,26 
Both of these metabolites are further demethylated to 
3-hydroxymorphinan. Dextrorphan is the active metabolite 
that produces neurobehavioral effects, while dextrometho-
rphan does not exhibit the same actions. Dextromethorphan 
is therefore a prodrug, and the metabolic conversion of dex-
tromethorphan to dextrorphan is an important determinant 
of the abuse potential of dextromethorphan in an individual. 
Experienced dextromethorphan users describe tachyphylaxis 
to the drug, but whether this effect is from alterations in cyto-
chrome function or other effects is not known.8
In therapeutic dosing, dextrorphan binds with high affin-
ity to σ-receptors to produce its antitussive activity without 
exhibiting classic opiate effects that occur from binding into 
µ and δ opiate receptors. In larger doses, dextrorphan, like 
phencyclidine and ketamine, antagonizes NMDA receptors by 
binding to the Ca2+ cation channel. Blockage of NMDA recep-
tors modulates excitatory neurotransmission, the end result of 
which is the production of specific neurobehavioral findings 
such as dissociative, “out-of-body” experiences. Dissociative 
agents also demonstrate adrenergic effects including hyper-
tension, tachycardia, and diaphoresis by inhibiting peripheral 
and central catecholamine uptake.27,28 Dextromethorphan also 
exhibits binding activity at serotonergic receptors, which may 
contribute to its abuse potential.29
CPHCS
The street cocktail “purple drank” is a concoction that can 
take several forms. Most involve some type of cough syrup 
containing the opiate agonist codeine and promethazine 
hydrochloride, an antihistamine with sedative properties. The 
cough syrup is typically mixed with a soft drink and candy, 
with some variants including alcohol.13
Codeine, or 3-methylmorphine, is a natural isomer 
of methylated morphine. It is a phenanthrenic alkaloid 
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with three fused benzene rings at its backbone.30 Codeine 
is the second-most predominant alkaloid in opium, with 
concentrations approaching 3%. Although codeine can be 
extracted from natural sources, a semi-synthetic process via 
methylation of morphine is the primary source of codeine 
for pharmaceutical use.31
Oral absorption of codeine from the gastrointestinal 
tract is almost complete (94% ± 4%). Onset of action occurs 
30–45 minutes after administration, when given orally.31 
Peak effect is reached within 1–2 hours, and the duration of 
antitussive action is 4–6 hours.31 Volume of distribution is 
found to be 3.6 L/kg, indicating extensive distribution of the 
drug into  tissues. Plasma protein binding is low at 7%–25%. 
 Pre-systemic metabolism is noted to be 50%, and metabolism 
is reported to be hepatic. Renal excretion accounts for the major 
elimination pathway, and the plasma half-life is 3 hours. Most 
of the excretion products appear in the urine within 6 hours, 
and 40%–60% of the codeine is excreted free or conjugated, 
approximately 5%–15% as free and conjugated morphine and 
10%–20% as free and conjugated norcodeine.31–33
Metabolism of codeine follows three major pathways: 
conjugation to codeine-6-glucuronide, N-demethylation to 
norcodeine, and O-demethylation to morphine (Figure 1). 
The conjugation pathway is quantitatively the most important, 
with codeine-6-glucuronide recovered in urine accounting 
for 70% of an oral dose of codeine. The corresponding val-
ues for N-demethylation and O-demethylation are probably 
7% and 5%, respectively; approximately 4% is excreted 
unchanged.19
Codeine, similar to dextromethorphan, is a prodrug 
and inactive opioid agonist, requiring metabolic activa-
tion by O-demethylation to morphine by CYP2D6. This 
typically represents a minor metabolite pathway for codeine 
 metabolism. N-demethylation into norcodeine by CYP3A4 
and glucuronidation are more prevalent but produce inactive 
metabolites. The need for conversion to morphine explains 
why approximately 5%–7% of White patients, who are devoid 
of CYP2D6 function, cannot derive an analgesic response 
from codeine. Rarely, ultra-rapid CYP2D6 metabolizers 
produce an unexpectedly large amount of morphine, with 
resulting life-threatening opioid toxicity.19
Promethazine hydrochloride is a phenothiazine deriva-
tive that acts primarily as a histamine (H1) receptor 
antagonist, with moderate muscarinic dopamine (D2)-receptor-
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blocking effects (Figure 2). It is used in cough syrups for its 
antihistaminic, antiemetic, and sedative effects.34
Promethazine hydrochloride is well absorbed from the 
gastrointestinal tract, with an average of 88% of the dose 
absorbed after oral administration. However, the absolute bio-
availability is only 25% because of first-pass clearance. Clini-
cal effects are apparent within 20 minutes after oral, rectal, or 
intramuscular administration, and the effects last 4–6 hours. 
Volume of distribution is found to be 13.4 L/kg, and plasma 
protein binding is 76%–93%. Promethazine undergoes 
extensive hepatic metabolism to a variety of metabolites. The 
sulfoxides of promethazine and N- demethylpro-methazine 
are the predominant metabolites and are excreted in the 
urine. Negligible amounts of unchanged drug are recov-
ered in the urine. The plasma half-life is approximately 
7–14 hours.34,35
Codeine is known to be subject to abuse for those in search 
of the subjective effects of euphoria, elation, analgesia, and 
“liking.” It has been postulated that O-demethylation metabo-
lite agonism at µ receptors contributes substantially to the 
abuse liability of codeine. Pretreatment with selective, potent 
CYP2D6 inhibitors like quinidine can produce a duration-
dependent inhibition of O-demethylation of codeine and a 
decrease in the positive subjective effects of codeine.36
Euphoria from promethazine is very rare, except with 
high intravenous doses and/or co-administration with opioids 
and other central nervous system depressants (alcohol).32 
The concern here of course is that “sizzurp” and other street 
concoctions contain exactly that: promethazine, codeine, and 
alcohol, along with other potential sedatives. Consuming 
large quantities of these drugs prolongs and intensifies each 
drug’s sedative effects and is responsible for an increase in 
life-threatening events.3,12
Clinical effects and toxicity
Dextromethorphan
The dose of ingested dextromethorphan determines the neu-
robehavioral outcome. Recreational users of dextromethorphan 
describe several intensities of effect from the drug, known 
as “plateaus.”37 The first plateau is a mild stimulant effect 
similar to that of methylenedioxymethamphetamine. The 
second plateau is described as similar to a combination of 
concurrent ethanol and marijuana intoxication, although 
some users describe hallucinations as occurring at this stage.38 
The third level is a dissociative, “out-of body” state, like that 
produced by a low recreational dose of ketamine, and the 
fourth plateau is a fully dissociative condition similar to 
that produced by ketamine intoxication.37 Neurobehavioral 
effects begin within 30–60 minutes of ingestion and persist 
for approximately 6 hours.
To produce nominal effects from dextromethorphan – the 
first plateau – online drug encyclopedias such as Erowid 
(http://www.erowid.org) describe a dose of between 100 and 
200 mg. The second plateau may be achieved with between 
200 and 400 mg, while the third plateau can be achieved with 
between 300 and 600 mg of the drug. An ingested dose of 
600–1,500 mg dextromethorphan may produce a full-blown 
dissociative state. These doses depend upon several factors, 
such as an individual’s CYP2D6 subtype and bodyweight, as 
well as the degree of tolerance to dextromethorphan.37
The clinical presentation of dextromethorphan intoxi-
cation therefore depends on the ingested dose. Minimally 
intoxicated persons may develop tachycardia, hypertension, 
vomiting, mydriasis, diaphoresis, nystagmus, euphoria, loss 
of motor coordination, and giggling or laughing.37 In addition 
to the above findings, persons with moderate intoxication may 
demonstrate hallucinations and a distinctive, plodding ataxic 
gait that has been compared with “zombie-like” walking.38 
Severely intoxicated individuals in a dissociated state may 
be agitated or somnolent.28,37,39,40 Extremely agitated patients 
may develop hyperthermia and metabolic acidosis.8
Experienced dextromethorphan users describe a rap-
idly developing and persistent tolerance to the drug.37 
Dependence on dextromethorphan is rarely described.41–43 
Although dextromethorphan is not thought to have addictive 
properties, susceptible individuals may develop craving and 
habitual use of the drug.39,44 An abstinence syndrome may 
be associated with cessation of dextromethorphan abuse that 
is characterized by dysphoria and intense cravings.41,43,45,46 
Toxic psychosis and cognitive deterioration may arise from 
chronic use of the drug.41,45,46
Toxicity in the setting of dextromethorphan abuse can 
arise from additional sources. OTC cough formulations 
frequently contain, in addition to dextromethorphan, other 
pharmaceutical agents such as chlorpheniramine, acet-
aminophen, or pseudoephedrine.47 Chlorpheniramine is an 
CH3
CH3
N
N
S
HCl•
CH3
Figure 2 Promethazine hydrochloride structure.
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H1-receptor antagonist. Consequently, individuals who have 
abused chlorpheniramine-containing dextromethorphan for-
mulations may also exhibit anticholinergic signs and symp-
toms (eg, tachycardia; warm, dry, flushed skin; dry mucosa; 
mydriasis; agitated delirium; urinary retention; and gastroin-
testinal dysmotility). Severe chlorpheniramine intoxication 
has also been associated with seizure activity, rhabdomyoly-
sis, and hyperthermia.40 Pseudoephedrine intoxication may 
mimic that of chlorpheniramine, except that patients may 
exhibit diaphoresis. In contrast, overdose of acetaminophen, 
an antipyretic and analgesic that is a component of over 
100 cough and cold preparations, produces delayed hepatic 
injury and, potentially, death. Lastly, because dextrometho-
rphan is produced as the crystalline hydrobromide salt, 
bromism is a rare consequence that has been identified in 
heavy chronic abusers of dextromethorphan.48 Bromism is 
caused by a neurotoxic effect on the brain, which results in 
somnolence, psychosis, seizures, and delirium.49
Drug interactions exist between dextromethorphan and 
other substances, the best characterized of which is serotonin 
syndrome. This condition typically occurs from the interaction 
between dextromethorphan and selective serotonin reuptake 
inhibitors or monoamine oxidase inhibitors, but concurrent 
administration of antibiotics (eg, linezolide), opiate analgesics 
(eg, meperidine and tramadol), or drugs of abuse (eg, Syrian 
rue) could precipitate the condition.50 Patients with serotonin 
syndrome may demonstrate the clinical triad of mental status 
changes, autonomic instability, and muscular hypertonicity.51
CPHCS
It is difficult to determine what constitutes a standard toxic 
or lethal dose of codeine. However, the lethal oral dose of 
codeine in an average adult is reported to be in the range of 
500–1,000 mg. One case reported a human death at 12 mg/kg 
and established a median lethal dose of 800 mg.52 Infants 
and children are believed to be relatively more sensitive to 
opiates on a bodyweight basis.31 Elderly patients are also 
comparatively intolerant to opiates.31
It is also difficult to predict the total amount of codeine 
or promethazine consumed by addicts on a daily basis to 
produce euphoric effects. Mattoo et al noted that the aver-
age level of use by addicts in northern India was clearly 
much beyond the therapeutic daily dose of 15–30 mL (all 
46 treatment-seeking patients consumed 60 mL or more per 
day, and in half of them the daily quantity ranged between 
200 and 500 mL).3 The standard formulation per 5 mL 
contained 9–15 mg of codeine and 3 mg of promethazine.2 
Erowid recommends a starting dose of 30–60 mg and states 
most people settle at the 250 mg per day mark to experience 
the best euphoria with the least side effects.52
Serious overdose with codeine is characterized by respi-
ratory depression (a decrease in respiratory rate and/or tidal 
volume, Cheyne–Stokes respiration, and cyanosis), extreme 
somnolence progressing to stupor or coma, skeletal muscle 
flaccidity, cold and clammy skin, and sometimes bradycardia 
and hypotension. The triad of coma, pinpoint pupils, and respi-
ratory depression is strongly suggestive of opiate poisoning. 
In severe overdosage, particularly by the intravenous route, 
apnea, circulatory collapse, cardiac arrest, and death may 
occur. Seizure activity may be related to hypoxia.  Promethazine 
may add to the depressant effects of codeine.31–33
Signs and symptoms of overdosage with promethazine 
HCl range from mild depression of the central nervous system 
and cardiovascular system to profound hypotension, respira-
tory depression, unconsciousness, and sudden death. The 
anti-cholinergic toxidrome with hyperthermia, flushing, tachy-
cardia, altered mental status, agitated delirium, dry mucosa, 
mydriasis, urinary retention, and gastrointestinal dysmotility 
may be seen. Other reported reactions include hyper-reflexia, 
hypertonia, ataxia, athetosis, and extensor-plantar reflexes 
(Babinski reflex).32 Stimulation may be evident, especially in 
children and geriatric patients. Convulsions may rarely occur. 
A paradoxical-type reaction has been reported in children 
receiving single doses of 75–125 mg orally, characterized by 
hyperexcitability and nightmares.32
CPHCS may interact with monoamine oxidase inhibitors 
causing increased extrapyramidal effects. An initial small 
test dose is advisable to allow observation of any excessive 
narcotic effects or monoamine oxidase inhibitor interaction. 
Promethazine may increase, prolong, or intensify the seda-
tive action of other central nervous system depressants, such 
as alcohol, sedatives/hypnotics (including barbiturates), 
narcotics, narcotic analgesics, general anesthetics, tricyclic 
antidepressants, and tranquilizers; therefore, such agents 
should be avoided or administered in reduced dosage to 
patients receiving promethazine HCl. Excessive amounts of 
promethazine HCl relative to a narcotic may lead to restless-
ness and motor hyperactivity in the patient with pain; these 
symptoms usually disappear with adequate control of the 
pain. Concomitant use of other agents with anticholinergic 
properties should also be undertaken with caution.32
Management of cough  
in addicted patients
A thorough review of the literature regarding OTC cough 
and cold medicines was carried out by Smith, Schroeder, and 
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Fahey and published in the Cochrane Database of  Systematic 
Reviews in 2012. In this review, the authors looked at 
26  trials (18 in adults, 8 in children) involving more than 
4,037 people.53
In the adult studies, six trials compared antitussives with 
placebo and had variable results. Two trials compared the 
expectorant guaifenesin with placebo; one indicated signifi-
cant benefit, whereas the other did not. One trial found that 
a mucolytic reduced cough frequency and symptom scores. 
Two studies examined antihistamine-decongestant combina-
tions and found conflicting results. Three trials found anti-
histamines were no more effective than placebo in relieving 
cough symptoms.53
In the children studies, antitussives (two studies), anti-
histamines (two studies), antihistamine decongestants (two 
studies), and antitussive/bronchodilator combinations (one 
study) were no more effective than placebo. The results 
of one trial favored active treatment with mucolytics over 
placebo.53
The results of this review suggest that there is no good 
evidence for or against the effectiveness of OTC medica-
tions in acute cough. Many studies were of low quality and 
very different from each other, making evaluation of overall 
efficacy difficult.53
Expectorants increase bronchial mucus production, thus 
making coughs more productive. Guaifenesin, a ubiquitous 
expectorant found in OTC cough medicines, has minimally 
toxic effects limited to mild gastrointestinal irritation.22 It 
can be considered a safer alternative for use in patients with 
addiction to or dependence on other antitussives with high 
abuse potential.
Benzonatate (Tessalon Perles; Pfizer, New York, NY, 
USA) is a non-narcotic butyl amine chemically related to ester 
anesthetics. It is thought to work by decreasing the sensitivity 
of stretch receptors in the lower airways and lung, making the 
cough reflex less active. Although benzonatate is a non-opioid 
and is not prone to abuse, it has a poor safety profile. There 
have been numerous reports of overdose resulting in neuro-
toxicity (seizures), cardiotoxicity (arrhythmias), and death, 
especially in children.54,55 A search of the United States Food 
and Drug Administration’s Adverse Event Reporting System 
(AERS) database through May 19, 2010 identified 31 cases of 
overdose associated with benzonatate (median age 18 years, 
range 1–66 years). Common adverse events reported in the 
overdose cases included cardiac arrest, coma, and convulsion. 
Of the 31 overdose cases reported in AERS, seven cases 
involved accidental ingestions, all in children under the age 
of 10 years. Five of the seven  accidental ingestions resulted 
in death in children aged 2 years and younger.56 Therefore, 
physicians should not routinely recommend benzonatate as 
an alternative antitussive, especially in children under the 
age of 10.
Patient and parental education
Given the lack of data that antitussive medications are effec-
tive in children and their potential toxic effects, it would seem 
that they possess questionable utility in the setting of acute 
upper respiratory infection. Physicians should rather focus on 
parental education concerning the expected brief course of 
the cough and congestion and the importance of maintaining 
adequate hydration during these situations. Parents should 
also be reminded of the importance of safe storage of OTC 
cough medicines as well as other drugs found in the house-
hold in order to prevent unintentional ingestion. Parents and 
patients alike should be reminded of the dangers of opioid 
abuse and pharmaceutical misuse and dependence.
The American Academy of Pediatrics Committee on 
Drugs issued a policy statement in 1997 regarding the use of 
codeine-containing and dextromethorphan-containing cough 
remedies in children.57 The Committee concluded that the 
absence of well controlled studies failed to supported the 
use of codeine- and dextromethorphan-containing cough 
suppressants in children, since most coughs in children are 
viral in origin and resolve with fluids and supportive care. 
Moreover, the fact that dosage recommendations in chil-
dren are extrapolated from adults increases the likelihood 
of preventable adverse events.57 For adults who are abusing 
or deemed dependent upon the euphoric effects of narcotic 
based cough and cold medicines, rehabilitation options for 
opioid addiction should be discussed and encouraged by 
providers.
Conclusion
Although abuse of dextromethorphan-containing cold and 
cough medicines is still prevalent, there has been a rise in 
the use of codeine-containing cough syrups, perhaps because 
of glorification of the effects by high profile figures in the 
mainstream media. Misuse and abuse of these products can be 
extraordinarily dangerous, resulting in serious neurotoxicity, 
cardiotoxicity, hepatotoxicity, and even death from respira-
tory failure. Health care professionals should be aware of the 
misuse and abuse potential of various antitussive medications. 
Efforts should be made to prescribe nonaddictive medications 
and to recommend alternative treatment options for cough and 
cold. Education of patients and parents to the dangers of these 
seemingly harmless OTC medications must be a top priority.
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